Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.49 |
| ▸ | FEN1 | P39748 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537604 | 0.85 | GPR119 (0.50) | GPR119DPP4ALOX5APFEN1SCN9A | |
| SCHEMBL23122533 | 0.85 | PDE4A (0.45) | GPR119ALOX5APFEN1KDM4EPKM | |
| SCHEMBL1104001 | 0.84 | GPR119 (0.48) | GPR119ALOX5APFEN1 | |
| SCHEMBL1103973 | 0.83 | ALOX5AP (0.47) | GPR119DPP4ALOX5APFEN1SCN9A | |
| SCHEMBL1103977 | 0.83 | GPR119 (0.55) | GPR119ALOX5APFEN1 | |
| SCHEMBL25394031 | 0.82 | GPR119 (0.53) | GPR119DPP4KDM4E | |
| SCHEMBL13535186 | 0.82 | GPR119 (0.51) | GPR119DPP4ALOX5APFEN1SCN9A | |
| SCHEMBL16519957 | 0.82 | SCN9A (0.51) | GPR119DPP4SCN9AFAAH | |
| SCHEMBL903963 | 0.81 | USP30 (0.47) | GPR119DPP4ALOX5APFEN1SCN9A | |
| SCHEMBL3113163 | 0.81 | ALOX5AP (0.49) | GPR119DPP4ALOX5APFEN1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334288-B2 | 4-phenoxymethylpiperidines as modulators of GPR119 activity | IRM LLC (BM) | 2012-12-18 | — | — | US | disclosed |
| US-8258156-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-09-04 | — | — | US | disclosed |
| US-8258156-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-09-04 | — | — | US | disclosed |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| WO-2010006191-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-14 | — | — | WO | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885DPP4 1268/4885ALOX5AP 943/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885DPP4 1268/4885ALOX5AP 943/4885 |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR4, GPR180 | GPR119 1/4885DPP4 975/4885ALOX5AP 852/4885 |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885DPP4 1268/4885ALOX5AP 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.